Back to All Events

POSTPONED: Arthritis Advisory Committee

The US FDA has postponed the March 17, 2015 the Arthritis Advisory Committee (AAC). The Committee meeting was scheduled to discuss the safety and efficacy of CT- P13, a proposed biosimilar to Janssen Biotech Inc.'s Remicade (infliximab), submitted by Celltrion, Inc. The FDA says that the reason for the postponement is that information requests are pending with the sponsor of the application. Tarius will monitor the Federal Register for announcements regarding this meeting.